Drugs / BAY207543
BAY207543
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03853538 | Jan → Mar 2019 | — | Bayer | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03852563 | Mar → Apr 2019 | — | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY207543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03852563 ↗ |
| Known as | Bepanthol | “BAY207543 (Bepanthol, Bepantol® Derma Spray)” NCT03853538 ↗1“BAY207543 (Bepanthol)” NCT03852563 ↗ |
| Known as | Bepantol Derma Spray | “BAY207543 (Bepanthol, Bepantol® Derma Spray)” NCT03853538 ↗ |
| Route | Topical | “Product is applied to one hemiface.” NCT03853538 ↗ |